All In Biotech

Drug Trial Radar · NCT06574568

A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

A Multicenter, Open-label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Efficacy of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Jun 14, 2024

Primary completion

Dec 31, 2026

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Excyte Biopharma LtdIndustry
Sponsor type
Industry
First posted
Aug 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to provide a basis for further clinical development of YKST02. YKST02 is a study medicine that targets multiple myeloma and activates the human body to fight against this disease.

Conditions

  • Relapsed or Refractory Multiple Myeloma

Interventions

  • YKST02Drug

    BCMA-CD3 bispecific antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Dose-limiting Toxicities (DLT)Time frame: 21 days after the first dose
  2. Incidence of Adverse Events (AEs)Time frame: up to 42 weeks
  3. Incidence of Serious Adverse Events (SAEs)Time frame: up to 42 weeks
  4. Overall Response Rate (ORR)Time frame: From the date of dosing until the date of first documented progression

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Chao-yang Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Jishuitan Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • Shunde Hospital of Southern Medical University

    Foshan, Guangdong, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • Sun Yat-sen Memorial Hospital

    Guangzhou, Guangdong, China · Not yet recruiting

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, China · Not yet recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • Affiliated Zhongshan Hospital of Dalian University

    Dalian, Liaoning, China · Recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Not yet recruiting

  • Shanxi Cancer hospital

    Taiyuan, Shanxi, China · Not yet recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.